66 related articles for article (PubMed ID: 28057155)
21. Effects of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeted combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma.
Kun Y; Wu J; Chen S
Pak J Med Sci; 2023; 39(3):742-746. PubMed ID: 37250563
[TBL] [Abstract][Full Text] [Related]
22. Serum sPD-L1 levels are elevated in patients with viral diseases, bacterial sepsis or in patients with impaired renal function compared to healthy blood donors.
Loacker L; Egger A; Fux V; Bellmann-Weiler R; Weiss G; Griesmacher A; Hoermann G; Ratzinger F; Haslacher H; Schrezenmeier H; Anliker M
Clin Chem Lab Med; 2023 Nov; 61(12):2248-2255. PubMed ID: 37401452
[TBL] [Abstract][Full Text] [Related]
23. Application of Lung-Targeted Lipid Nanoparticle-delivered mRNA of soluble PD-L1 via SORT Technology in Acute Respiratory Distress Syndrome.
Sun H; Zhang Y; Wang J; Su J; Zhou D; Yu X; Xu Y; Yang W
Theranostics; 2023; 13(14):4974-4992. PubMed ID: 37771784
[No Abstract] [Full Text] [Related]
24. Association of soluble PD-L1 and NLR combination with 1-Year mortality in patients with COVID-19.
Akhmaltdinova L; Mekhantseva I; Turgunova L; Kostinov M; Zhumadilova Z; Turmukhambetova A
Int Immunopharmacol; 2024 Mar; 129():111600. PubMed ID: 38325048
[TBL] [Abstract][Full Text] [Related]
25. Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy.
Tanizaki J; Kuroda H; Yokoyama T; Takahama M; Shoda H; Nakamura A; Kitamura Y; Mamesaya N; Kadota Y; Sawa K; Okishio K; Okada M; Suminaka C; Noda K; Sakai K; Chiba Y; Nishio K; Chamoto K; Honjo T; Yamamoto N; Nakagawa K; Hayashi H
JTO Clin Res Rep; 2023 Dec; 4(12):100590. PubMed ID: 38029041
[TBL] [Abstract][Full Text] [Related]
26. Role of sPD-1 and sPD-Ls in the pathogenesis of connective tissue disease.
He H; He X; Zhou M; Tang Y; Dai L; Xie Z; Wang Y; Xie C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):444-454. PubMed ID: 37164928
[TBL] [Abstract][Full Text] [Related]
27. Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19.
Sabbatino F; Pagliano P; Sellitto C; Stefanelli B; Corbi G; Manzo V; De Bellis E; Liguori L; Salzano FA; Pepe S; Filippelli A; Conti V
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959277
[TBL] [Abstract][Full Text] [Related]
28. Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers.
Zhou X; Wang Y; Bao M; Chu Y; Liu R; Chen Q; Lin Y
Appl Microbiol Biotechnol; 2024 Feb; 108(1):221. PubMed ID: 38372795
[TBL] [Abstract][Full Text] [Related]
29. Development of a microcantilever-based biosensor for detecting Programmed Death Ligand 1.
Neairat T; Al-Gawati M; Tul Ain Q; Assaifan AK; Alshamsan A; Alarifi A; Alodhayb AN; Alzahrani KE; Albrithen H
Saudi Pharm J; 2024 Jun; 32(6):102051. PubMed ID: 38812944
[TBL] [Abstract][Full Text] [Related]
30. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma.
Uysal M; Beypinar I; Araz M
J Cancer Res Ther; 2024 Jan; ():. PubMed ID: 38261436
[TBL] [Abstract][Full Text] [Related]
31. DUSP22 inhibits lung tumorigenesis by suppression of EGFR/c-Met signaling.
Lin HH; Chang CW; Liao YT; Yeh SD; Lin HP; Ho HM; Cheung CH; Juan HF; Chen YR; Su YW; Chen LM; Tan TH; Lin WJ
Cell Death Discov; 2024 Jun; 10(1):285. PubMed ID: 38877005
[TBL] [Abstract][Full Text] [Related]
32. Breast metastasis from EGFR-mutated lung adenocarcinoma: A case report and review of the literature.
Ota T; Hasegawa Y; Okimura A; Sakashita K; Sunami T; Yukimoto K; Sawada R; Sakamoto K; Fukuoka M
Clin Case Rep; 2018 Aug; 6(8):1510-1516. PubMed ID: 30147894
[TBL] [Abstract][Full Text] [Related]
33. Correction.
Publisher T
Monaldi Arch Chest Dis; 2023 Oct; 93(4):. PubMed ID: 37846734
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Expression and Its Prognostic Value in Different Tumor Specimens in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
Mo DC; Chen L; Wu Y; Huang JF; Liang XJ
J Clin Oncol; 2024 May; ():JCO2400230. PubMed ID: 38754073
[No Abstract] [Full Text] [Related]
35. Retracted: Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.
International BR
Biomed Res Int; 2024; 2024():9865398. PubMed ID: 38230195
[TBL] [Abstract][Full Text] [Related]
36. Discussion to: Oncological characteristics of EGFR-mutated clinical stage IA lung adenocarcinoma with radiologically pure-solid appearance.
J Thorac Cardiovasc Surg; 2024 Jan; ():. PubMed ID: 38189703
[No Abstract] [Full Text] [Related]
37. VEGF inhibitors in
Alexander M; Halmos B
Ann Transl Med; 2018 Dec; 6(23):446. PubMed ID: 30603634
[No Abstract] [Full Text] [Related]
38. Advanced Lung Adenocarcinoma with Multiple Cardiac Masses.
Keramida K; Malaxianaki E; Katinioti A; Kliridis P; Trikas A
Balkan Med J; 2024 Apr; ():. PubMed ID: 38571327
[No Abstract] [Full Text] [Related]
39. Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.
Gniadek TJ; Li QK; Tully E; Chatterjee S; Nimmagadda S; Gabrielson E
Mod Pathol; 2017 Apr; 30(4):530-538. PubMed ID: 28059094
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.
Hutarew G
Memo; 2016; 9(4):201-206. PubMed ID: 28058063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
